In plain terms

The claim being assessed: Accumulated free-radical-mediated macromolecular damage is a primary rate-limiting driver of normal organismal aging, and reducing that damage through antioxidant intervention extends lifespan or healthspan, including in humans.

Where the evidence stands: Β — Association only. The pattern is real and repeatable, but nobody has shown it causes anything.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: The registered weakest-link rule yields Β from SC1 Β, SC2 Γ and SC3 Γ. This bundled score must not be read as denying experimentally demonstrated redox contributions. The primary-driver sensitivity is Γ. Selected lesion protection can reach a contextual causal level, but cannot substitute for organismal primacy or human healthy-life extension.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means for Free Radical Theory of Aging — original broad FRTA

Claim being assessed: Accumulated free-radical-mediated macromolecular damage is a primary rate-limiting driver of normal organismal aging, and reducing that damage through antioxidant intervention extends lifespan or healthspan, including in humans.. This review asks whether the proposed factor causes the health outcome—not just whether the two appear together. For the wording assessed here, the evidence is rated Association only (HSEF Β; Moderate confidence). The pattern is real and repeatable, but nobody has shown it causes anything. That rating applies to this claim and scope; it does not mean the biological process is irrelevant in every setting.

Implications for health and treatment: This is an assessment of a causal explanation, not proof that a particular supplement, diet, test, or treatment improves health. A treatment claim needs studies that test the intervention in people and measure meaningful benefits and harms. These findings can help frame research and informed clinical questions, but they do not identify what is right for one person.

Limits for individual care: Evidence from cells, animals, associations, or a plausible mechanism may not predict what happens in people. The grade is limited to the exact claim, outcomes, and sources reviewed, and it is not a diagnosis or an individual forecast. Do not start, stop, or change care based on this page; discuss personal decisions with a qualified clinician.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

This assessment rests on 68 sources and 72 individually checked claims. 72 of those claims were verified against the original paper.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

ID	Sub-claim	Type	Level	Pivotal card
SC1	Oxidative macromolecular damage increases with normal age.	existence	Β	—
SC2	Free-radical-mediated damage is a primary rate-limiting cause required for normal organismal aging.	necessity	Γ	Card ↗
SC3	Antioxidant reduction of free-radical damage extends human lifespan or healthspan.	application	Γ	Card ↗

Visual Evidence Cards · Pivotal Subclaims

Pivotal subclaim illustrations

Dark-theme simulated-micrograph renders and concise causal evidence summaries for the pivotal subclaims that govern this review's grade. Click any card to inspect the master 2400×2400 render.

Master 2400×2400 render ↗

Master 2400×2400 render ↗

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 68 primary reports; claims: 72; verified: 72; unverified: 0. Verification is bounded attribution. Access: 3 partial-body and 65 complete abstract/status examinations. Cutoff: 2026-10-05. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-06. 3 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Oxidative injury contributes to specific aging phenotypes, but broad damage primacy and general human antioxidant antiaging benefit are not established.

Deciding experiment: Preregister an adult-onset, compartment-specific ROS-lesion intervention in genetically diverse male and female mice at independent sites, alongside a signalling-preserving orthogonal lesion-clearance intervention, then translate a target-engaged formulation to an adequately powered older-adult clinical trial.

Belief versus evidence: The registered weakest-link rule yields Β from SC1 Β, SC2 Γ and SC3 Γ. This bundled score must not be read as denying experimentally demonstrated redox contributions. The primary-driver sensitivity is Γ. Selected lesion protection can reach a contextual causal level, but cannot substitute for organismal primacy or human healthy-life extension.

Best-supported rival: Multifactorial damage and compensation. Adult-onset, compartment-selective lesion reduction with an orthogonal signalling-preserving manipulation would distinguish damage reduction from adaptive signalling and disease-specific protection.

COMPETING MECHANISTIC MODELS

Rank 1: Multifactorial damage and compensation (Ε). Aging combines heterogeneous damage, repair, disease and compensatory responses; ROS may be both signals and damaging intermediates. Sod2 damage–survival dissociation and tissue-specific Sod1 rescue fit this bounded model. This broad model risks flexibility and does not identify every rate-limiting pathway.

Rank 2: Adaptive redox signalling / hormesis (Ε). Location, dose and timing determine whether ROS trigger adaptive protection. Worm antioxidant blockade, mitochondrial superoxide signalling and fly reverse transport support this mechanism in defined contexts. These experiments do not establish universal mammalian or human hormetic longevity.

Rank 3: Mutation and mitochondrial quality (Γ). Mutation spectra, apoptosis and mitochondrial maintenance can alter survival without a simple ROS feedback loop. PolG and Mgme1 comparisons distinguish mutation pathways and lesion spectra. Forced developmental mutation loads are not normal aging and do not exclude redox amplification.

Rank 4: Nutrient sensing and hyperfunction (Γ). Metabolic signalling, intake and growth can mediate longevity independently of measured oxidative damage. Irs1-null longevity and calorie-related NAC confounding motivate this comparator. This selected corpus is not a full independent review of nutrient-sensing primacy.

Rank 5: Broad damage-primacy FRTA (Γ). Accumulated radical-mediated lesions primarily limit normal aging and their removal extends healthy life. mCAT, female G6PD survival, invertebrate OSER1 and selected functional trials support narrower redox intervention effects. Sod2 damage dissociation, SOD-null worms, heterogeneous drug effects and human outcome nulls block the broad claim.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

Accumulated free-radical-mediated macromolecular damage is a primary rate-limiting driver of normal organismal aging, and reducing that damage through antioxidant intervention extends lifespan or healthspan, including in humans.

Use the index weakest-link rule for the bundled damage-driver and antioxidant-application claim. The user explicitly selected original broad FRTA, not MFRTA. SC1 association, SC2 endogenous causal necessity and SC3 human application are distinct; mitochondrial vicious-cycle results do not alone falsify every ROS mechanism.

Selection: public-interest rank 11 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

Evidence and causal interpretation

The strongest positive animal evidence is targeted rather than generic. mCAT prolongs mouse survival; G6PD improves function and female median survival; OSER1 modifies invertebrate survival. Severe Sod1 deficiency also produces damaging phenotypes and tissue rescue can improve them. These findings support particular redox contributions, while tissue lineages and pleiotropic mechanisms constrain the broad FRTA inference [1,6,15,24,52,58,68].

The direct countertests are stronger than an absence of supportive citations. Sod2 reduction increased lesions and tumours without shortened survival, and MnSOD overexpression reduced oxidation without longer life. Some antioxidant-defense deletions in worms leave life normal or longer. Hu’s positive SOD2 mouse result is retained beside Jang’s null rather than hidden. Compartment and adaptive signalling are plausible reasons that bulk damage and survival do not move monotonically [2–14,18,28–32].

Human clinical endpoints must be separated from target exposure and short physiology. Large randomized vitamin trials generally failed to improve major outcomes; some caused harm. SU.VI.MAX male cancer findings and the WHS secondary cardiovascular-death result are retained. MitoQ vascular physiology and the small GlyNAC functional RCT provide narrower positive signals; newer physical-function MitoQ was overall null [34–51].

Original Lizzo Methods/Results correct an inference suggested by the abstract: 117 were randomized, 114 completed, and the primary placebo-adjusted GSH endpoint was null. Its favorable deficient/high-stress subgroup comparison was post hoc and within treated participants. It is a hypothesis-generating biochemical response, not a confirmed between-arm functional benefit [38].

Mutation-induced progeria does not stand in for normal aging, and mCAT rescue of a PolG heart phenotype does not prove a ROS-initiated mitochondrial vicious cycle. Human muscle mutations are observational. NDGA, NAC and comparative species experiments add real boundaries involving sex, dietary intake, lesion-specific mortality and assay effects [25–27,53–67].

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: weakest-link. The registered weakest-link rule yields Β from SC1 Β, SC2 Γ and SC3 Γ. This bundled score must not be read as denying experimentally demonstrated redox contributions. The primary-driver sensitivity is Γ. Selected lesion protection can reach a contextual causal level, but cannot substitute for organismal primacy or human healthy-life extension. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[1] Mitochondrial catalase increased median and maximal murine survival with lower peroxide and damage markers. Compartment-specific genetic protection does not establish broad radical-damage primacy in humans; sex, attrition and supplemental methods were not examined.

[2] Lifelong Sod2 haploinsufficiency increased oxidative DNA damage and tumour incidence without shortening mean or maximum survival. A partial enzyme reduction with compensation does not eliminate every damaging radical pathway.

[3] Several single and paired antioxidant transgenes had null survival effects; body text specifies 44–54 animals per cohort and two- to fourfold expression. Peroxisomal catalase is not a replication of mitochondrial catalase; protected husbandry and a single mouse background limit generalization.

[4] Approximately twofold MnSOD expression lowered lipid peroxidation and improved paraquat resistance and mitochondrial ATP maintenance without survival or pathology benefit. Assays demonstrate some engagement, not complete elimination of compartment-specific ROS; original body retrieval failed.

[5] A separate SOD2 transgenic study reported extended survival but no rescue of age-related memory or synaptic plasticity. This positive result must be retained beside Jang's null; design differences and one mouse background preclude a universal conclusion.

[6] Sod1 deficiency caused widespread damage, shortened life and frequent late liver neoplasia. Severe antioxidant deficiency and tumour-driven mortality need not reproduce the rate-limiting process in normal aging.

[7] Sod3 deletion did not shorten life and did not further shorten Sod1-null survival despite potentiated stress markers. This tests specific SOD compartments, not all oxidative lesions or every endogenous compensation.

[8] Combined Sod2/Gpx1 deficiency increased DNA/protein damage and neoplasia without reducing longevity. The normal survival result is informative but genotype-specific; lesion distribution and compensation remain possible boundaries.

[9] Worms lacking all five SOD genes retained normal lifespan despite marked acute-stress sensitivity. Worm superoxide signalling and adaptation are not mammalian aging; loss of SOD is not absence of all redox defense.

[10] Manipulating worm SOD isoforms produced little lifespan change and did not remove daf-2 longevity. Specific nematode genotypes constrain the necessity inference; stress defense and longevity remain separate endpoints.

[11] SOD deletions did not reduce baseline or dietary-restricted worm longevity, although sod-1 affected cold-induced extension. Cold-dependent protection is a real boundary rather than a universal null antioxidant effect.

[12] Male Trx2 transgenic mice had lower mitochondrial ROS and lipid oxidation but no significant survival-curve or aggregate pathology improvement. Small numerical survival shifts are not established extension; the reported publication year is 2020 despite later indexing.

[13] Mitochondrial mutant worms required a superoxide signal for longer survival; antioxidants removed and mild paraquat phenocopied the effect. This supports context-dependent signalling rather than universal benefit from prooxidants or human antioxidant harm.

[14] SOD loss interacted differently with respiratory-complex mutants, including extension in one context and lethality in another. Complex-specific genetic interactions cannot be collapsed into a single ROS-dose rule.

[15] mCAT attenuated age-related cardiac functional, fibrosis and oxidation changes; cardiac risk measures predicted mortality. Follow-up in the mCAT experimental lineage is not independent proof that all aging tissues slow uniformly.

[16] Neuron-specific Sod1 reduction produced limited weakness and junction changes without the full global-knockout sarcopenia phenotype. Tissue-specific deficiency did not fully reproduce global loss; this does not negate a combined neuron-muscle redox contribution.

[17] Neuronal SOD1 rescue normalized muscle radical signal and muscle mass in global Sod1-null mice while low perfusion persisted. An induced deficiency rescue is not normal-aging lifespan extension or proof that perfusion mediates the mass benefit.

[18] In clk-1 worms mitochondrial superoxide increases extended life whereas cytoplasmic superoxide increases shortened it. The sensitized genetic background limits extrapolation; ROS location matters as well as quantity.

[19] UCP2 absence increased stress and shortened mouse life; tissue uncoupling correlated with interspecies survival. Uncoupling alters energetics and more than radical damage, preventing isolation of a single damage mechanism.

[20] Progressive fly SOD2 reduction increased age-dependent mortality, neuronal damage and behavioral decline without reduced developmental viability. Severe deficiency and surplus enzyme activity constrain inference to ordinary unperturbed human aging.

[21] Sod2 haploinsufficiency did not further shorten telomere-deficient mouse life or worsen stem-cell maintenance. The induced telomere context is narrower than normal aging; a linked erratum was detected but its contents were not examined.

[22] Embryonic reversible SOD2 knockdown induced persistent antioxidant and mitochondrial adaptation in adult mouse tissues. The experiment reports adaptation, not normal-aging lifespan extension, and specifically begins during development.

[23] Adult worm peroxiredoxin repression left lifespan and protein damage unchanged but reduced fitness and ATP. Lack of lesion engagement and compensatory uncoupling limit a damage-primacy falsification.

[24] Aged mCAT mice retained muscle force, calcium handling and voluntary exercise with less RyR1 oxidation. A tissue-functional follow-up in the mCAT line is not a separate lifespan replication or demonstration of human benefit.

[25] mCAT partially rescued cardiomyopathy and oxidative changes in PolG-mutator mice. A progeroid disease cross demonstrates lesion amplification, not primary ROS initiation of normal aging.

[27] Maternal mitochondrial mutations shortened life even with wild-type nuclear background. Developmental mutation exposure does not identify radicals as the cause of these mutations or all normal aging.

[28] The original p66Shc deletion report found stress resistance and longer mouse life with cellular rescue of stress signalling. Later multi-site and environmental tests question survival generality; the protein also regulates energetics and apoptosis.

[29] Metformin-induced ROS and PRDX-2 signalling contributed to longer worm survival. Drug pleiotropy and worm physiology prevent a human antiaging or universal prooxidant inference.

[30] Early developmental ROS linked to altered chromatin and longer subsequent worm life with redox-sensitive cultured-cell methyltransferases. Developmental programming is not a late-life rescue or demonstration of human aging-rate modification.

[31] Increasing reverse-electron-transport ROS extended fly life and rescued PINK1-linked phenotypes. The source-specific signal does not imply that chronic bulk oxidative injury is harmless.

[32] sod-2 deletion extended worm life despite higher protein oxidation and reduced oxygen consumption. Mitochondrial compensation and genotype interactions limit transfer to mammalian redox deficiency.

[34] Plasma from MitoQ-treated older participants improved cultured endothelial NO and reduced mitochondrial ROS; oxLDL/LOX-1 manipulation narrowed a mediator. This ancillary analysis uses the earlier crossover trial's samples and is not independent clinical replication or lifespan evidence.

[35] A 20-person six-week MitoQ crossover trial improved flow-mediated dilation and lowered oxidized LDL. Vascular physiology in selected older adults is narrower than durable healthspan; stiffness analysis was a baseline-defined subgroup.

[36] MitoQ improved physical function in old male mice but gave no convincing overall physical-function benefit in the 18-person human crossover trial. Age-70 subgroup signals are exploratory; human cohort overlap with earlier MitoQ publications requires confirmation.

[37] A 22-person parallel trial lowered muscle peroxide emission capacity without altering basal redox state or acute exercise signalling. Short-term muscle physiology does not test mortality or all potential long-term clinical benefits.

[38] Original Methods/Results report 117 randomized and 114 completing two weeks; all doses were null for the primary placebo-adjusted total-GSH endpoint. The high-stress/low-GSH subset result was post hoc and within treated participants, not a confirmed between-arm functional-healthspan effect.

[39] Twenty-four older adults were randomized 12 per arm for 16 weeks; the abstract reports improved functional and metabolic domains with GlyNAC. Small size, numerous outcomes and unavailable original endpoint/attrition details prevent durable healthspan or mediated-aging claims.

[41] Vitamin C/E attenuated exercise-associated insulin-sensitivity and redox-defense adaptations in young men. Four-week training adaptation is not lifespan and does not prove every antioxidant interferes with every exercise regimen.

[42] Worm glucose restriction increased respiration/ROS and lifespan; antioxidant treatment blocked extension. The metabolic intervention and redox signal are model-specific, not an instruction to induce oxidative injury in humans.

[43] The 9541-person HOPE vitamin E comparison did not reduce primary cardiovascular events or all-cause death over 4.5 years. A high-risk clinical population and one regimen cannot exclude all compartment-specific redox interventions.

[44] Extended HOPE follow-up retained null major endpoints and detected increased heart-failure risk. This is an extension of the HOPE family with participation losses, not an independent trial or proof of universal antioxidant harm.

[45] CARET found increased lung cancer and all-cause mortality with beta-carotene/retinol in smokers and asbestos-exposed adults. Baseline exposure and combined high-dose supplements restrict generalization to other formulations and nonsmokers.

[46] SU.VI.MAX was broadly null overall but reported a sex interaction for cancer and a benefit in men. The mortality sex interaction was not significant; a nutritional-status or sex effect is not general human aging reversal.

[47] PHS II vitamin E/C did not reduce major cardiovascular events or mortality; vitamin E increased hemorrhagic stroke. Factorial design and male physicians define scope; exposure to vitamins is not verified selective intracellular lesion removal.

[48] SELECT follow-up found higher prostate-cancer incidence with vitamin E and no preventive selenium benefit. This tests prostate-cancer prevention in men, not a generic antioxidant mechanism across all tissues.

[49] HPS increased circulating vitamin levels substantially without reducing mortality, vascular events or cancer over five years. Blood exposure is established, but selective tissue radical-damage engagement and biological-aging mediation are not.

[50] WHS found null primary cardiovascular/cancer outcomes and total mortality despite a secondary cardiovascular-death reduction. The favorable secondary endpoint must be retained but does not establish an overall healthspan or aging-rate benefit.

[51] ATBC beta-carotene increased lung cancer and total mortality; vitamin E did not lower total mortality. Male smokers and particular doses define scope; secondary prostate and hemorrhagic-stroke findings are endpoint-specific.

[52] G6PD transgenic mice had higher NADPH, lower oxidative damage, better age-related function and longer female median survival. NADPH has multiple biological roles; sex-specific survival does not establish radical-damage primacy across mammals.

[53] Vitamin C/E lowered liver lipid peroxidation but shortened field-vole survival in both temperature settings. DNA damage was unchanged and species-specific toxicity or signalling can differ from mouse and human effects.

[54] Proofreading-deficient PolG mice developed mutations, shortened life and progeroid features. Forced mutation burden is not proof that radical damage normally initiates organismal aging.

[55] A separate PolG model associated progeria with mtDNA mutations and apoptosis without increased oxidative-stress markers. Absence of tested markers is not absence of every transient ROS event; this mainly challenges a mitochondrial vicious cycle.

[56] Mgme1 loss generated mitochondrial deletions without progeria. Different mutation spectra and distributions constrain inference; mitochondrial defects cannot be treated as interchangeable aging causes.

[58] Liver SOD1 restoration partly rescued Sod1-null longevity and hepatic pathology without rescuing muscle deficits. Organ-specific rescue in severe deficiency suggests lesion-specific mortality; normal mouse aging remains a distinct question.

[60] p66Shc deletion was counterselected under outdoor food competition and cold, with energetic and reproductive deficits. Extrinsic hazards differ from protected-laboratory aging; environmental dependence is a boundary, not a direct aging-rate measurement.

[61] Two institutions found no general p66Shc survival benefit across sexes/backgrounds, apart from a limited calorie-restriction survival percentile. The partial favorable result does not reproduce the original overall longevity claim; protein pleiotropy persists.

[62] Three-site heterogeneous mouse tests found male-specific median-life benefit from NDGA and different effects of metabolic comparators. Drug effects cannot be assigned to antioxidant chemistry without mediation; female and maximum-survival boundaries matter.

[63] NDGA extended fly/mouse survival in selected dosing conditions but increased severe terminal pathology in mice. Survival benefit and health benefit diverge; dose-unit inconsistencies in the abstract require original dosing confirmation before numerical reuse.

[64] ITP NDGA and aspirin increased male median survival across sites without a significant 90th-percentile-survival effect. Shared ITP methods and multifactorial drug actions do not isolate radical-damage mediation or generalize to females.

[65] NAC extended male heterogeneous mouse life, while later-started comparators were null. The authors identify inadvertent dietary restriction as a possible explanation; it is not a clean antioxidant-mechanism test.

[66] ITP replicated male NDGA median-life extension without maximal-life extension and found male benefit with an Nrf2-inducing mixture. Additional cohorts share platform and controls; Nrf2 signalling and botanical mixtures are not selective damage removal.

[67] Three-site nematode tests found GTE/NDGA benefits and harms varying by species, strain and manual versus automated assay. Original body shows functional and stress-resistance outcomes dissociate from lifespan; scanner light and handling differences remain possible mechanisms.

[68] OSER1 perturbation altered oxidative stress and lifespan in multiple invertebrates; human variants associated with longevity. Protein mitochondrial/reproductive functions and observational human genetics do not isolate damage mediation or human necessity.

Tally: 63 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Shared cohorts, experimental platforms, transgenic lineages and repeated outcomes do not constitute fully independent causal lines.

Cap audit, precedence and Β/Γ/Δ boundary

The Β cap binds SC1’s age/damage association. Γ binds extrapolation to broad primacy and durable human healthy-life extension. Narrow adult functional or lesion-specific interventions are acknowledged as causal in their tested setting; neither a single mouse transgene nor a short human physiological endpoint establishes the full claim. Generic human vitamin nulls test those regimens, not every selective redox intervention. No additional categorical refutation downgrade is stacked onto these scope ceilings.

Gamma hard-rule audit: Biomarkers alone do not cross the aging-trajectory boundary. Species, strain, developmental timing and nonspecific interventions constrain the scope of each result.

SC1 cap: “Association with aging or age-related biomarkers without intervention-driven trajectory change caps at Β.” Age-associated damage is observed in multiple tissues and humans, but this existence/age relationship is observational; it is not a causal-aging assertion.

SC2 cap: “Mechanistic plausibility plus one-species or in vitro support caps at Γ.” Targeted protection and severe-deficiency rescue show real local causal effects. Bidirectional damage–survival dissociations, compensatory signals and mutation models prevent inference to primary rate-limiting normal aging across organisms.

SC3 cap: “Mechanistic plausibility plus one-species or in vitro support caps at Γ.” Positive small human functional/vascular trials coexist with functional nulls and large clinical supplement nulls or harms. They have not demonstrated a durable extension of human healthy life with selective radical-damage mediation.

SC1 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Age-associated damage is observed in multiple tissues and humans, but this existence/age relationship is observational; it is not a causal-aging assertion.

SC2 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Targeted protection and severe-deficiency rescue show real local causal effects. Bidirectional damage–survival dissociations, compensatory signals and mutation models prevent inference to primary rate-limiting normal aging across organisms.

SC3 field-valid definition: “ - Genetic or pharmacologic intervention producing reproducible lifespan/healthspan extension - Must separate developmental effects from true aging effects - Biomarker change alone does NOT satisfy this threshold” Positive full-scope result: no. Positive small human functional/vascular trials coexist with functional nulls and large clinical supplement nulls or harms. They have not demonstrated a durable extension of human healthy life with selective radical-damage mediation.

Upward threshold ladder

SC1 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A validated longitudinal tissue-lesion relationship would strengthen the existence subclaim; causal intervention cannot be silently substituted for the registered observational statement.

SC2 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. Replicated adult-onset lesion reduction across diverse mammals, both sexes and independent labs with aging trajectories, lesion-specific rescue and signalling controls.

SC3 Δ: “Requires at least one intervention changing lifespan or healthspan in a way consistent with the hypothesis.” Satisfied: no. A replicated randomized older-adult trial with target engagement and durable clinical function or disability-free survival, separating nutrient correction and signalling from lesion mediation.

Upper ladder: Upper levels are live options. Human genetics, orthogonal interventions, natural experiments and cross-context replication were considered; none establishes the entire registered claim merely by changing a correlated biomarker.

Independence: Distinct methods can exclude different errors, but neither source count nor the number of outcomes is an independence argument.

Falsification and pitfalls

Damage changes without lifespan change. Sod2 haploinsufficiency, MnSOD overexpression and combined Sod2/Gpx1 deficiency; these constrain a monotonic damage-primacy model. Additional downgrade: False.

Effects change across backgrounds or species. p66Shc replication/environment, sex-specific NDGA and manual/automated nematode assays. Additional downgrade: False.

Biomarker shift treated as aging reversal. Short GSH and mitochondrial assays are separated from lasting clinical healthspan.

Single-species or strain findings generalized. mCAT, G6PD and SOD models retain explicit genotype and tissue boundaries.

Lifespan extension treated as mechanism proof. NAC calorie confounding, NDGA pleiotropy and UCP2 energetics remain unresolved.

MFRTA substituted for broad FRTA. PolG results constrain mitochondrial feedback without refuting every radical mechanism.

Adversarial steelman: above, then below

SC2’s next rung Δ is attractive because adult interventions can improve function and survival. It is rejected for the registered primary rate-limiting claim: those results do not isolate global normal-aging primacy. SC1 cannot be promoted beyond Β by borrowing an intervention that tests a different causal statement.

Α would neglect directly measured age-related damage and extensive biological experiments. A blanket refutation would also erase mCAT, G6PD, OSER1 and selected human functional benefits.

Keep Β for the bundle and Γ for the driver sensitivity; retain all positive context-specific causal observations without converting them into general human antiaging proof.

Final score, causal direction and M/S/D

The registered weakest-link rule yields Β from SC1 Β, SC2 Γ and SC3 Γ. This bundled score must not be read as denying experimentally demonstrated redox contributions. The primary-driver sensitivity is Γ. Selected lesion protection can reach a contextual causal level, but cannot substitute for organismal primacy or human healthy-life extension.

For the redox component, bidirectional production and feedback are documented, so neither purely downstream nor purely epiphenomenal adequately describes all scoped lesions (steps 1–2 unresolved globally). Normal aging is not abolished by the tested reductions and rate-limiting initiation is not established (steps 3–4 fail). Tissue injury is amplified or maintained in defined contexts, supporting step 5, reinforcing / stabilizing factor. This role is not inferred from tournament rank.

Momentum: Decisive work underway. OSER1 2024, three-site nematode comparisons 2024, muscle MitoQ 2025 and translational physical-function MitoQ 2026 are named active mechanistic/functional tests in the examined corpus.

Stability: Stable. No named pending result is asserted to be likely to move the registered score imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Preregister an adult-onset, compartment-specific ROS-lesion intervention in genetically diverse male and female mice at independent sites, alongside a signalling-preserving orthogonal lesion-clearance intervention, then translate a target-engaged formulation to an adequately powered older-adult clinical trial.

Readout: Lifespan plus longitudinal frailty, mobility, cognition and organ function; in humans durable clinical function and disability-free survival rather than a redox marker alone. Controls: Pair-feeding, developmental-timing exclusion, pharmacokinetics, compartment-specific lesion quantification, redox-signalling measures, common husbandry and prospective endpoint multiplicity handling. Supporting: Concordant functional aging trajectories and survival with specific lesion mediation across backgrounds and independent modalities. Falsifying: Adequate lesion reduction without trajectory benefit, or benefits explained entirely by food intake, transient signalling or one lethal disease.

RESEARCH TIMELINE

KNOWLEDGE GAPS

Which chemically defined lesions, rather than bulk ROS assays, actually limit particular normal-aging tissues?

Can adult-onset protection improve multiple functional trajectories reproducibly across sex, background and husbandry while preserving adaptive signalling?

Will prespecified target-engaged human trials reproduce GlyNAC or MitoQ functional effects with durable clinical endpoints?

How much of mouse survival extension represents delayed cancer or cardiac disease rather than a general aging-rate change?

Do independent antioxidant modalities converge after controlling intake, mitochondrial energetics and shared cohort reuse?

METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Returned Methods/Results passages were reconciled with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful passage checks are distinguished from provider summaries. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

REVIEWER NOTES

68 original reports were appraised. Three original articles received selected-body examination; other cards explicitly remain abstract/status based. Europe PMC body failures and NCBI responses without article bodies were retained. Consensus Pro mislabeled Jang as Pérez; its sample-size details are not promoted to verified original-body facts. Consensus failed to retrieve Lizzo and Murray despite their primary records being available directly. Its SOD gap-table empty cell is a provider-coverage artifact, not evidence of no target-engagement experiments. No quantitative dose from the inconsistent NDGA abstract is reused. Linked errata are detected, not asserted resolved.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-06.

Scope of checks. All 68 reference PMIDs verified against PubMed metadata (title, first author, year, journal, DOI) — 68/68 resolve to the stated record; no retraction or expression-of-concern notice was found for any of them. Eleven load-bearing claims were spot-checked against the cited abstracts or the retained original passages (mCAT survival, Sod2 haploinsufficiency, MnSOD overexpression, SOD2-transgenic longevity versus the Jang null, Sod1-null hepatocarcinogenesis, SOD-null worm lifespan, the GlyNAC randomised trial numbers and primary endpoint, HOPE, HPS, ATBC and WHS clinical outcomes). Scoring logic was re-derived from references/hsef-framework.md and SKILL.md Steps 3, 8–12: hard caps are applied per subclaim before thresholds, the index-prescribed weakest-link rule is applied as written (Β from SC1 Β, SC2 Γ, SC3 Γ), and the reported alternative-rule sensitivities (primary-subclaim Γ, scope-matched Γ) are arithmetically correct for this matrix.

Findings.

The matching citation strings in free-radical-aging.scorecard.json were corrected to the same text. No evidence card, number, direction of effect, subclaim level, confidence or aggregation result changed.

Rejected findings (checked, no change). (a) Eleven references carry a print/issue year one later than PubMed's e-publication year (refs 3, 5, 7, 11, 26, 33, 60–63, 67); the review uses the print year consistently and flags the convention explicitly for ref 12, so this is not an error. (b) The bundled Β letter was tested against the alternative reading that SC2's targeted protection results (mCAT, G6PD, neuronal Sod1 rescue) should lift the bundle: universal cap 3 ("Overexpression in model systems caps at Γ") and cap 2 bind these items, so Γ is the ceiling for SC2 and the weakest-link bundle remains Β. (c) The pairing of a positive SOD2-transgenic survival result with the MnSOD-overexpression null is a defensible retention of discordant evidence, not an inconsistency.

Residual limitations. Verification depth is abstract/metadata plus the three retained partial bodies; no complete-paper or supplement audit was performed by either model. Consensus was not re-run during this adversarial pass.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-06.

REFERENCES

1. Schriner SE, Linford NJ, Martin GM et al. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science (New York, N.Y.). 2005. PMID 15879174. DOI: 10.1126/science.1106653. Access: abstract_metadata. Study: mCAT lineage.

2. Van Remmen H, Ikeno Y, Hamilton M et al. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiological genomics. 2003. PMID 14679299. DOI: 10.1152/physiolgenomics.00122.2003. Access: abstract_metadata. Study: PMID14679299.

3. Pérez VI, Van Remmen H, Bokov A et al. The overexpression of major antioxidant enzymes does not extend the lifespan of mice. Aging cell. 2009. PMID 19077044. DOI: 10.1111/j.1474-9726.2008.00449.x. Access: full_text_partial. Study: PMID19077044.

4. Jang YC, Pérez VI, Song W et al. Overexpression of Mn superoxide dismutase does not increase life span in mice. The journals of gerontology. Series A, Biological sciences and medical sciences. 2009. PMID 19633237. DOI: 10.1093/gerona/glp100. Access: abstract_metadata. Study: PMID19633237.

5. Hu D, Cao P, Thiels E et al. Hippocampal long-term potentiation, memory, and longevity in mice that overexpress mitochondrial superoxide dismutase. Neurobiology of learning and memory. 2007. PMID 17129739. DOI: 10.1016/j.nlm.2006.10.003. Access: abstract_metadata. Study: PMID17129739.

6. Elchuri S, Oberley TD, Qi W et al. CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life. Oncogene. 2005. PMID 15531919. DOI: 10.1038/sj.onc.1208207. Access: abstract_metadata. Study: PMID15531919.

7. Sentman ML, Granström M, Jakobson H et al. Phenotypes of mice lacking extracellular superoxide dismutase and copper- and zinc-containing superoxide dismutase. The Journal of biological chemistry. 2006. PMID 16377630. DOI: 10.1074/jbc.M510764200. Access: abstract_metadata. Study: PMID16377630.

8. Zhang Y, Ikeno Y, Qi W et al. Mice deficient in both Mn superoxide dismutase and glutathione peroxidase-1 have increased oxidative damage and a greater incidence of pathology but no reduction in longevity. The journals of gerontology. Series A, Biological sciences and medical sciences. 2009. PMID 19776219. DOI: 10.1093/gerona/glp132. Access: abstract_metadata. Study: PMID19776219.

9. Van Raamsdonk JM, Hekimi S et al. Superoxide dismutase is dispensable for normal animal lifespan. Proceedings of the National Academy of Sciences of the United States of America. 2012. PMID 22451939. DOI: 10.1073/pnas.1116158109. Access: abstract_metadata. Study: PMID22451939.

10. Doonan R, McElwee JJ, Matthijssens F et al. Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans. Genes & development. 2008. PMID 19056880. DOI: 10.1101/gad.504808. Access: abstract_metadata. Study: PMID19056880.

11. Yen K, Patel HB, Lublin AL et al. SOD isoforms play no role in lifespan in ad lib or dietary restricted conditions, but mutational inactivation of SOD-1 reduces life extension by cold. Mechanisms of ageing and development. 2009. PMID 19059428. DOI: 10.1016/j.mad.2008.11.003. Access: abstract_metadata. Study: PMID19059428.

12. Roman MG, Flores LC, Cunningham GM et al. Thioredoxin overexpression in mitochondria showed minimum effects on aging and age-related diseases in male C57BL/6 mice. Aging pathobiology and therapeutics. 2020. PMID 35356005. DOI: 10.31491/apt.2020.03.009. Access: abstract_metadata. Study: PMID35356005.

13. Yang W, Hekimi S et al. A mitochondrial superoxide signal triggers increased longevity in Caenorhabditis elegans. PLoS biology. 2010. PMID 21151885. DOI: 10.1371/journal.pbio.1000556. Access: abstract_metadata. Study: PMID21151885.

14. Suthammarak W, Somerlot BH, Opheim E et al. Novel interactions between mitochondrial superoxide dismutases and the electron transport chain. Aging cell. 2013. PMID 23895727. DOI: 10.1111/acel.12144. Access: abstract_metadata. Study: PMID23895727.

15. Dai DF, Santana LF, Vermulst M et al. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation. 2009. PMID 19451351. DOI: 10.1161/CIRCULATIONAHA.108.822403. Access: abstract_metadata. Study: mCAT lineage.

16. Sataranatarajan K, Qaisar R, Davis C et al. Neuron specific reduction in CuZnSOD is not sufficient to initiate a full sarcopenia phenotype. Redox biology. 2015. PMID 25917273. DOI: 10.1016/j.redox.2015.04.005. Access: abstract_metadata. Study: PMID25917273.

17. Ahn B, Smith N, Saunders D et al. Using MRI to measure in vivo free radical production and perfusion dynamics in a mouse model of elevated oxidative stress and neurogenic atrophy. Redox biology. 2019. PMID 31470261. DOI: 10.1016/j.redox.2019.101308. Access: abstract_metadata. Study: PMID31470261.

18. Schaar CE, Dues DJ, Spielbauer KK et al. Mitochondrial and cytoplasmic ROS have opposing effects on lifespan. PLoS genetics. 2015. PMID 25671321. DOI: 10.1371/journal.pgen.1004972. Access: abstract_metadata. Study: PMID25671321.

19. Andrews ZB, Horvath TL et al. Uncoupling protein-2 regulates lifespan in mice. American journal of physiology. Endocrinology and metabolism. 2009. PMID 19141680. DOI: 10.1152/ajpendo.90903.2008. Access: abstract_metadata. Study: PMID19141680.

20. Paul A, Belton A, Nag S et al. Reduced mitochondrial SOD displays mortality characteristics reminiscent of natural aging. Mechanisms of ageing and development. 2007. PMID 18078670. DOI: 10.1016/j.mad.2007.10.013. Access: abstract_metadata. Study: PMID18078670.

21. Guachalla LM, Ju Z, Koziel R et al. Sod2 haploinsufficiency does not accelerate aging of telomere dysfunctional mice. Aging. 2009. PMID 20195488. DOI: 10.18632/aging.100030. Access: abstract_metadata. Study: PMID20195488.

22. Cox CS, McKay SE, Holmbeck MA et al. Mitohormesis in Mice via Sustained Basal Activation of Mitochondrial and Antioxidant Signaling. Cell metabolism. 2018. PMID 30122556. DOI: 10.1016/j.cmet.2018.07.011. Access: abstract_metadata. Study: PMID30122556.

23. Ranjan M, Gruber J, Ng LF et al. Repression of the mitochondrial peroxiredoxin antioxidant system does not shorten life span but causes reduced fitness in Caenorhabditis elegans. Free radical biology & medicine. 2013. PMID 23722165. DOI: 10.1016/j.freeradbiomed.2013.05.025. Access: abstract_metadata. Study: PMID23722165.

24. Umanskaya A, Santulli G, Xie W et al. Genetically enhancing mitochondrial antioxidant activity improves muscle function in aging. Proceedings of the National Academy of Sciences of the United States of America. 2014. PMID 25288763. DOI: 10.1073/pnas.1412754111. Access: abstract_metadata. Study: mCAT lineage.

25. Dai DF, Chen T, Wanagat J et al. Age-dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria. Aging cell. 2010. PMID 20456298. DOI: 10.1111/j.1474-9726.2010.00581.x. Access: abstract_metadata. Study: mCAT x PolG lineage.

26. Page MM, Withers DJ, Selman C et al. Longevity of insulin receptor substrate1 null mice is not associated with increased basal antioxidant protection or reduced oxidative damage. Age (Dordrecht, Netherlands). 2013. PMID 22371226. DOI: 10.1007/s11357-012-9395-9. Access: abstract_metadata. Study: PMID22371226.

27. Ross JM, Coppotelli G, Hoffer BJ et al. Maternally transmitted mitochondrial DNA mutations can reduce lifespan. Scientific reports. 2014. PMID 25299268. DOI: 10.1038/srep06569. Access: abstract_metadata. Study: PMID25299268.

28. Migliaccio E, Giorgio M, Mele S et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 1999. PMID 10580504. DOI: 10.1038/46311. Access: abstract_metadata. Study: PMID10580504.

29. De Haes W, Frooninckx L, Van Assche R et al. Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. Proceedings of the National Academy of Sciences of the United States of America. 2014. PMID 24889636. DOI: 10.1073/pnas.1321776111. Access: abstract_metadata. Study: PMID24889636.

30. Bazopoulou D, Knoefler D, Zheng Y et al. Developmental ROS individualizes organismal stress resistance and lifespan. Nature. 2019. PMID 31801997. DOI: 10.1038/s41586-019-1814-y. Access: abstract_metadata. Study: PMID31801997.

31. Scialò F, Sriram A, Fernández-Ayala D et al. Mitochondrial ROS Produced via Reverse Electron Transport Extend Animal Lifespan. Cell metabolism. 2016. PMID 27076081. DOI: 10.1016/j.cmet.2016.03.009. Access: abstract_metadata. Study: PMID27076081.

32. Van Raamsdonk JM, Hekimi S et al. Deletion of the mitochondrial superoxide dismutase sod-2 extends lifespan in Caenorhabditis elegans. PLoS genetics. 2009. PMID 19197346. DOI: 10.1371/journal.pgen.1000361. Access: abstract_metadata. Study: PMID19197346.

33. Ungvari Z, Csiszar A, Sosnowska D et al. Testing predictions of the oxidative stress hypothesis of aging using a novel invertebrate model of longevity: the giant clam (Tridacna derasa). The journals of gerontology. Series A, Biological sciences and medical sciences. 2013. PMID 22904097. DOI: 10.1093/gerona/gls159. Access: abstract_metadata. Study: PMID22904097.

34. Murray KO, Ludwig KR, Darvish S et al. Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress. American journal of physiology. Heart and circulatory physiology. 2023. PMID 37326998. DOI: 10.1152/ajpheart.00270.2023. Access: abstract_metadata. Study: MitoQ NCT02597023 family.

35. Rossman MJ, Santos-Parker JR, Steward CAC et al. Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults. Hypertension (Dallas, Tex. : 1979). 2018. PMID 29661838. DOI: 10.1161/HYPERTENSIONAHA.117.10787. Access: abstract_metadata. Study: MitoQ NCT02597023 family.

36. Murray KO, Gioscia-Ryan RA, Justice JN et al. Translational studies of chronic supplementation with a mitochondria-targeted antioxidant to improve physical function with ageing. The Journal of physiology. 2026. PMID 41733122. DOI: 10.1113/JP289428. Access: abstract_metadata. Study: MitoQ crossover family overlap unresolved.

37. Broome SC, Whitfield J, Janssens K et al. MitoQ supplementation does not impact redox responses to acute exercise in skeletal muscle of older individuals. Redox biology. 2025. PMID 41308251. DOI: 10.1016/j.redox.2025.103927. Access: abstract_metadata. Study: PMID41308251.

38. Lizzo G, Migliavacca E, Lamers D et al. A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. Frontiers in aging. 2022. PMID 35821844. DOI: 10.3389/fragi.2022.852569. Access: full_text_partial. Study: PMID35821844.

39. Kumar P, Liu C, Suliburk J et al. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. The journals of gerontology. Series A, Biological sciences and medical sciences. 2023. PMID 35975308. DOI: 10.1093/gerona/glac135. Access: abstract_metadata. Study: GlyNAC NCT01870193.

40. Kumar P, Liu C, Hsu JW et al. Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clinical and translational medicine. 2021. PMID 33783984. DOI: 10.1002/ctm2.372. Access: abstract_metadata. Study: GlyNAC pilot; separate from randomized report unless overlap shown.

41. Ristow M, Zarse K, Oberbach A et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proceedings of the National Academy of Sciences of the United States of America. 2009. PMID 19433800. DOI: 10.1073/pnas.0903485106. Access: abstract_metadata. Study: PMID19433800.

42. Schulz TJ, Zarse K, Voigt A et al. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell metabolism. 2007. PMID 17908557. DOI: 10.1016/j.cmet.2007.08.011. Access: abstract_metadata. Study: PMID17908557.

43. The Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Dagenais G et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The New England journal of medicine. 2000. PMID 10639540. DOI: 10.1056/NEJM200001203420302. Access: abstract_metadata. Study: HOPE family.

44. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005. PMID 15769967. DOI: 10.1001/jama.293.11.1338. Access: abstract_metadata. Study: HOPE family.

45. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. The New England journal of medicine. 1996. PMID 8602180. DOI: 10.1056/NEJM199605023341802. Access: abstract_metadata. Study: PMID8602180.

46. Hercberg S, Galan P, Preziosi P et al. The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Archives of internal medicine. 2004. PMID 15557412. DOI: 10.1001/archinte.164.21.2335. Access: abstract_metadata. Study: PMID15557412.

47. Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2008. PMID 18997197. DOI: 10.1001/jama.2008.600. Access: abstract_metadata. Study: PMID18997197.

48. Klein EA, Thompson IM, Tangen CM et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011. PMID 21990298. DOI: 10.1001/jama.2011.1437. Access: abstract_metadata. Study: PMID21990298.

49. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (London, England). 2002. PMID 12114037. DOI: 10.1016/S0140-6736(02)09328-5. Access: abstract_metadata. Study: PMID12114037.

50. Lee IM, Cook NR, Gaziano JM et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005. PMID 15998891. DOI: 10.1001/jama.294.1.56. Access: abstract_metadata. Study: PMID15998891.

51. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The New England journal of medicine. 1994. PMID 8127329. DOI: 10.1056/NEJM199404143301501. Access: abstract_metadata. Study: PMID8127329.

52. Nóbrega-Pereira S, Fernandez-Marcos PJ, Brioche T et al. G6PD protects from oxidative damage and improves healthspan in mice. Nature communications. 2016. PMID 26976705. DOI: 10.1038/ncomms10894. Access: abstract_metadata. Study: PMID26976705.

53. Selman C, McLaren JS, Collins AR et al. Deleterious consequences of antioxidant supplementation on lifespan in a wild-derived mammal. Biology letters. 2013. PMID 23825087. DOI: 10.1098/rsbl.2013.0432. Access: abstract_metadata. Study: PMID23825087.

54. Trifunovic A, Wredenberg A, Falkenberg M et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature. 2004. PMID 15164064. DOI: 10.1038/nature02517. Access: abstract_metadata. Study: PMID15164064.

55. Kujoth GC, Hiona A, Pugh TD et al. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science (New York, N.Y.). 2005. PMID 16020738. DOI: 10.1126/science.1112125. Access: abstract_metadata. Study: PMID16020738.

56. Matic S, Jiang M, Nicholls TJ et al. Mice lacking the mitochondrial exonuclease MGME1 accumulate mtDNA deletions without developing progeria. Nature communications. 2018. PMID 29572490. DOI: 10.1038/s41467-018-03552-x. Access: abstract_metadata. Study: PMID29572490.

57. Chabi B, Mousson de Camaret B, Chevrollier A et al. Random mtDNA deletions and functional consequence in aged human skeletal muscle. Biochemical and biophysical research communications. 2005. PMID 15896715. DOI: 10.1016/j.bbrc.2005.04.153. Access: abstract_metadata. Study: PMID15896715.

58. Zhang Y, Liu Y, Walsh M et al. Liver specific expression of Cu/ZnSOD extends the lifespan of Sod1 null mice. Mechanisms of ageing and development. 2016. PMID 26839948. DOI: 10.1016/j.mad.2016.01.005. Access: abstract_metadata. Study: PMID26839948.

59. Andziak B, O'Connor TP, Qi W et al. High oxidative damage levels in the longest-living rodent, the naked mole-rat. Aging cell. 2006. PMID 17054663. DOI: 10.1111/j.1474-9726.2006.00237.x. Access: abstract_metadata. Study: PMID17054663.

60. Giorgio M, Berry A, Berniakovich I et al. The p66Shc knocked out mice are short lived under natural condition. Aging cell. 2012. PMID 22081964. DOI: 10.1111/j.1474-9726.2011.00770.x. Access: abstract_metadata. Study: PMID22081964.

61. Ramsey JJ, Tran D, Giorgio M et al. The influence of Shc proteins on life span in mice. The journals of gerontology. Series A, Biological sciences and medical sciences. 2014. PMID 24336818. DOI: 10.1093/gerona/glt198. Access: abstract_metadata. Study: PMID24336818.

62. Harrison DE, Strong R, Allison DB et al. Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging cell. 2014. PMID 24245565. DOI: 10.1111/acel.12170. Access: abstract_metadata. Study: ITP NDGA platform; distinct cohorts.

63. Spindler SR, Mote PL, Lublin AL et al. Nordihydroguaiaretic Acid Extends the Lifespan of Drosophila and Mice, Increases Mortality-Related Tumors and Hemorrhagic Diathesis, and Alters Energy Homeostasis in Mice. The journals of gerontology. Series A, Biological sciences and medical sciences. 2015. PMID 25380600. DOI: 10.1093/gerona/glu190. Access: abstract_metadata. Study: PMID25380600.

64. Strong R, Miller RA, Astle CM et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging cell. 2008. PMID 18631321. DOI: 10.1111/j.1474-9726.2008.00414.x. Access: abstract_metadata. Study: ITP NDGA platform; distinct cohorts.

65. Flurkey K, Astle CM, Harrison DE et al. Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice. The journals of gerontology. Series A, Biological sciences and medical sciences. 2010. PMID 20819793. DOI: 10.1093/gerona/glq155. Access: abstract_metadata. Study: PMID20819793.

66. Strong R, Miller RA, Antebi A et al. Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer. Aging cell. 2016. PMID 27312235. DOI: 10.1111/acel.12496. Access: abstract_metadata. Study: ITP NDGA platform; distinct cohorts.

67. Banse SA, Sedore CA, Johnson E et al. Antioxidants green tea extract and nordihydroguaiaretic acid confer species and strain-specific lifespan and health effects in Caenorhabditis nematodes. GeroScience. 2024. PMID 37923874. DOI: 10.1007/s11357-023-00978-0. Access: full_text_partial. Study: PMID37923874.

68. Song J, Li Z, Zhou L et al. FOXO-regulated OSER1 reduces oxidative stress and extends lifespan in multiple species. Nature communications. 2024. PMID 39164296. DOI: 10.1038/s41467-024-51542-z. Access: abstract_metadata. Study: PMID39164296.

Source-specific evidence cards

[1] Extension of murine life span by overexpression of catalase targeted to mitochondria.

Shows: Mitochondrial catalase increased median and maximal murine survival with lower peroxide and damage markers.

Does not show: Compartment-specific genetic protection does not establish broad radical-damage primacy in humans; sex, attrition and supplemental methods were not examined.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[2] Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging.

Shows: Lifelong Sod2 haploinsufficiency increased oxidative DNA damage and tumour incidence without shortening mean or maximum survival.

Does not show: A partial enzyme reduction with compensation does not eliminate every damaging radical pathway.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[3] The overexpression of major antioxidant enzymes does not extend the lifespan of mice.

Shows: Several single and paired antioxidant transgenes had null survival effects; body text specifies 44–54 animals per cohort and two- to fourfold expression.

Does not show: Peroxisomal catalase is not a replication of mitochondrial catalase; protected husbandry and a single mouse background limit generalization.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 0:Main text (unsectioned body paragraphs). No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[4] Overexpression of Mn superoxide dismutase does not increase life span in mice.

Shows: Approximately twofold MnSOD expression lowered lipid peroxidation and improved paraquat resistance and mitochondrial ATP maintenance without survival or pathology benefit.

Does not show: Assays demonstrate some engagement, not complete elimination of compartment-specific ROS; original body retrieval failed.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[5] Hippocampal long-term potentiation, memory, and longevity in mice that overexpress mitochondrial superoxide dismutase.

Shows: A separate SOD2 transgenic study reported extended survival but no rescue of age-related memory or synaptic plasticity.

Does not show: This positive result must be retained beside Jang's null; design differences and one mouse background preclude a universal conclusion.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[6] CuZnSOD deficiency leads to persistent and widespread oxidative damage and hepatocarcinogenesis later in life.

Shows: Sod1 deficiency caused widespread damage, shortened life and frequent late liver neoplasia.

Does not show: Severe antioxidant deficiency and tumour-driven mortality need not reproduce the rate-limiting process in normal aging.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[7] Phenotypes of mice lacking extracellular superoxide dismutase and copper- and zinc-containing superoxide dismutase.

Shows: Sod3 deletion did not shorten life and did not further shorten Sod1-null survival despite potentiated stress markers.

Does not show: This tests specific SOD compartments, not all oxidative lesions or every endogenous compensation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[8] Mice deficient in both Mn superoxide dismutase and glutathione peroxidase-1 have increased oxidative damage and a greater incidence of pathology but no reduction in longevity.

Shows: Combined Sod2/Gpx1 deficiency increased DNA/protein damage and neoplasia without reducing longevity.

Does not show: The normal survival result is informative but genotype-specific; lesion distribution and compensation remain possible boundaries.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[9] Superoxide dismutase is dispensable for normal animal lifespan.

Shows: Worms lacking all five SOD genes retained normal lifespan despite marked acute-stress sensitivity.

Does not show: Worm superoxide signalling and adaptation are not mammalian aging; loss of SOD is not absence of all redox defense.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[10] Against the oxidative damage theory of aging: superoxide dismutases protect against oxidative stress but have little or no effect on life span in Caenorhabditis elegans.

Shows: Manipulating worm SOD isoforms produced little lifespan change and did not remove daf-2 longevity.

Does not show: Specific nematode genotypes constrain the necessity inference; stress defense and longevity remain separate endpoints.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[11] SOD isoforms play no role in lifespan in ad lib or dietary restricted conditions, but mutational inactivation of SOD-1 reduces life extension by cold.

Shows: SOD deletions did not reduce baseline or dietary-restricted worm longevity, although sod-1 affected cold-induced extension.

Does not show: Cold-dependent protection is a real boundary rather than a universal null antioxidant effect.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[12] Thioredoxin overexpression in mitochondria showed minimum effects on aging and age-related diseases in male C57BL/6 mice.

Shows: Male Trx2 transgenic mice had lower mitochondrial ROS and lipid oxidation but no significant survival-curve or aggregate pathology improvement.

Does not show: Small numerical survival shifts are not established extension; the reported publication year is 2020 despite later indexing.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[13] A mitochondrial superoxide signal triggers increased longevity in Caenorhabditis elegans.

Shows: Mitochondrial mutant worms required a superoxide signal for longer survival; antioxidants removed and mild paraquat phenocopied the effect.

Does not show: This supports context-dependent signalling rather than universal benefit from prooxidants or human antioxidant harm.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[14] Novel interactions between mitochondrial superoxide dismutases and the electron transport chain.

Shows: SOD loss interacted differently with respiratory-complex mutants, including extension in one context and lethality in another.

Does not show: Complex-specific genetic interactions cannot be collapsed into a single ROS-dose rule.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[15] Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging.

Shows: mCAT attenuated age-related cardiac functional, fibrosis and oxidation changes; cardiac risk measures predicted mortality.

Does not show: Follow-up in the mCAT experimental lineage is not independent proof that all aging tissues slow uniformly.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[16] Neuron specific reduction in CuZnSOD is not sufficient to initiate a full sarcopenia phenotype.

Shows: Neuron-specific Sod1 reduction produced limited weakness and junction changes without the full global-knockout sarcopenia phenotype.

Does not show: Tissue-specific deficiency did not fully reproduce global loss; this does not negate a combined neuron-muscle redox contribution.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[17] Using MRI to measure in vivo free radical production and perfusion dynamics in a mouse model of elevated oxidative stress and neurogenic atrophy.

Shows: Neuronal SOD1 rescue normalized muscle radical signal and muscle mass in global Sod1-null mice while low perfusion persisted.

Does not show: An induced deficiency rescue is not normal-aging lifespan extension or proof that perfusion mediates the mass benefit.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[18] Mitochondrial and cytoplasmic ROS have opposing effects on lifespan.

Shows: In clk-1 worms mitochondrial superoxide increases extended life whereas cytoplasmic superoxide increases shortened it.

Does not show: The sensitized genetic background limits extrapolation; ROS location matters as well as quantity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[19] Uncoupling protein-2 regulates lifespan in mice.

Shows: UCP2 absence increased stress and shortened mouse life; tissue uncoupling correlated with interspecies survival.

Does not show: Uncoupling alters energetics and more than radical damage, preventing isolation of a single damage mechanism.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[20] Reduced mitochondrial SOD displays mortality characteristics reminiscent of natural aging.

Shows: Progressive fly SOD2 reduction increased age-dependent mortality, neuronal damage and behavioral decline without reduced developmental viability.

Does not show: Severe deficiency and surplus enzyme activity constrain inference to ordinary unperturbed human aging.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[21] Sod2 haploinsufficiency does not accelerate aging of telomere dysfunctional mice.

Shows: Sod2 haploinsufficiency did not further shorten telomere-deficient mouse life or worsen stem-cell maintenance.

Does not show: The induced telomere context is narrower than normal aging; a linked erratum was detected but its contents were not examined.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMID31879376. Subclaims: SC2.

[22] Mitohormesis in Mice via Sustained Basal Activation of Mitochondrial and Antioxidant Signaling.

Shows: Embryonic reversible SOD2 knockdown induced persistent antioxidant and mitochondrial adaptation in adult mouse tissues.

Does not show: The experiment reports adaptation, not normal-aging lifespan extension, and specifically begins during development.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[23] Repression of the mitochondrial peroxiredoxin antioxidant system does not shorten life span but causes reduced fitness in Caenorhabditis elegans.

Shows: Adult worm peroxiredoxin repression left lifespan and protein damage unchanged but reduced fitness and ATP.

Does not show: Lack of lesion engagement and compensatory uncoupling limit a damage-primacy falsification.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[24] Genetically enhancing mitochondrial antioxidant activity improves muscle function in aging.

Shows: Aged mCAT mice retained muscle force, calcium handling and voluntary exercise with less RyR1 oxidation.

Does not show: A tissue-functional follow-up in the mCAT line is not a separate lifespan replication or demonstration of human benefit.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[25] Age-dependent cardiomyopathy in mitochondrial mutator mice is attenuated by overexpression of catalase targeted to mitochondria.

Shows: mCAT partially rescued cardiomyopathy and oxidative changes in PolG-mutator mice.

Does not show: A progeroid disease cross demonstrates lesion amplification, not primary ROS initiation of normal aging.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[26] Longevity of insulin receptor substrate1 null mice is not associated with increased basal antioxidant protection or reduced oxidative damage.

Shows: Long-lived Irs1-null mice did not show broadly higher basal antioxidant protection or less measured oxidation.

Does not show: Cross-sectional markers in a longevity genotype cannot exclude all temporal or localized redox mechanisms.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[27] Maternally transmitted mitochondrial DNA mutations can reduce lifespan.

Shows: Maternal mitochondrial mutations shortened life even with wild-type nuclear background.

Does not show: Developmental mutation exposure does not identify radicals as the cause of these mutations or all normal aging.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[28] The p66shc adaptor protein controls oxidative stress response and life span in mammals.

Shows: The original p66Shc deletion report found stress resistance and longer mouse life with cellular rescue of stress signalling.

Does not show: Later multi-site and environmental tests question survival generality; the protein also regulates energetics and apoptosis.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[29] Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2.

Shows: Metformin-induced ROS and PRDX-2 signalling contributed to longer worm survival.

Does not show: Drug pleiotropy and worm physiology prevent a human antiaging or universal prooxidant inference.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[30] Developmental ROS individualizes organismal stress resistance and lifespan.

Shows: Early developmental ROS linked to altered chromatin and longer subsequent worm life with redox-sensitive cultured-cell methyltransferases.

Does not show: Developmental programming is not a late-life rescue or demonstration of human aging-rate modification.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[31] Mitochondrial ROS Produced via Reverse Electron Transport Extend Animal Lifespan.

Shows: Increasing reverse-electron-transport ROS extended fly life and rescued PINK1-linked phenotypes.

Does not show: The source-specific signal does not imply that chronic bulk oxidative injury is harmless.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[32] Deletion of the mitochondrial superoxide dismutase sod-2 extends lifespan in Caenorhabditis elegans.

Shows: sod-2 deletion extended worm life despite higher protein oxidation and reduced oxygen consumption.

Does not show: Mitochondrial compensation and genotype interactions limit transfer to mammalian redox deficiency.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[33] Testing predictions of the oxidative stress hypothesis of aging using a novel invertebrate model of longevity: the giant clam (Tridacna derasa).

Shows: Giant clams did not consistently show lower ROS or higher antioxidant defense than short-lived scallops but resisted an oxidant challenge.

Does not show: Species ecology and proteostasis confound longevity comparisons; challenge survival is not a manipulated normal-aging trajectory.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[34] Chronic mitochondria antioxidant treatment in older adults alters the circulating milieu to improve endothelial cell function and mitochondrial oxidative stress.

Shows: Plasma from MitoQ-treated older participants improved cultured endothelial NO and reduced mitochondrial ROS; oxLDL/LOX-1 manipulation narrowed a mediator.

Does not show: This ancillary analysis uses the earlier crossover trial's samples and is not independent clinical replication or lifespan evidence.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[35] Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults.

Shows: A 20-person six-week MitoQ crossover trial improved flow-mediated dilation and lowered oxidized LDL.

Does not show: Vascular physiology in selected older adults is narrower than durable healthspan; stiffness analysis was a baseline-defined subgroup.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[36] Translational studies of chronic supplementation with a mitochondria-targeted antioxidant to improve physical function with ageing.

Shows: MitoQ improved physical function in old male mice but gave no convincing overall physical-function benefit in the 18-person human crossover trial.

Does not show: Age-70 subgroup signals are exploratory; human cohort overlap with earlier MitoQ publications requires confirmation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[37] MitoQ supplementation does not impact redox responses to acute exercise in skeletal muscle of older individuals.

Shows: A 22-person parallel trial lowered muscle peroxide emission capacity without altering basal redox state or acute exercise signalling.

Does not show: Short-term muscle physiology does not test mortality or all potential long-term clinical benefits.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[38] A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage.

Shows: Original Methods/Results report 117 randomized and 114 completing two weeks; all doses were null for the primary placebo-adjusted total-GSH endpoint.

Does not show: The high-stress/low-GSH subset result was post hoc and within treated participants, not a confirmed between-arm functional-healthspan effect.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Materials and Methods, 2:Results. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[39] Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial.

Shows: Twenty-four older adults were randomized 12 per arm for 16 weeks; the abstract reports improved functional and metabolic domains with GlyNAC.

Does not show: Small size, numerous outcomes and unavailable original endpoint/attrition details prevent durable healthspan or mediated-aging claims.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[40] Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial.

Shows: Eight older adults improved multiple biochemical and functional measures during GlyNAC treatment and declined after withdrawal.

Does not show: Open-label repeated testing without concurrent placebo leaves practice, regression and expectation effects unresolved.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[41] Antioxidants prevent health-promoting effects of physical exercise in humans.

Shows: Vitamin C/E attenuated exercise-associated insulin-sensitivity and redox-defense adaptations in young men.

Does not show: Four-week training adaptation is not lifespan and does not prove every antioxidant interferes with every exercise regimen.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[42] Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress.

Shows: Worm glucose restriction increased respiration/ROS and lifespan; antioxidant treatment blocked extension.

Does not show: The metabolic intervention and redox signal are model-specific, not an instruction to induce oxidative injury in humans.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[43] Vitamin E supplementation and cardiovascular events in high-risk patients.

Shows: The 9541-person HOPE vitamin E comparison did not reduce primary cardiovascular events or all-cause death over 4.5 years.

Does not show: A high-risk clinical population and one regimen cannot exclude all compartment-specific redox interventions.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[44] Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.

Shows: Extended HOPE follow-up retained null major endpoints and detected increased heart-failure risk.

Does not show: This is an extension of the HOPE family with participation losses, not an independent trial or proof of universal antioxidant harm.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[45] Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.

Shows: CARET found increased lung cancer and all-cause mortality with beta-carotene/retinol in smokers and asbestos-exposed adults.

Does not show: Baseline exposure and combined high-dose supplements restrict generalization to other formulations and nonsmokers.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[46] The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals.

Shows: SU.VI.MAX was broadly null overall but reported a sex interaction for cancer and a benefit in men.

Does not show: The mortality sex interaction was not significant; a nutritional-status or sex effect is not general human aging reversal.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. ErratumIn: PMIDnot supplied. Subclaims: SC3.

[47] Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial.

Shows: PHS II vitamin E/C did not reduce major cardiovascular events or mortality; vitamin E increased hemorrhagic stroke.

Does not show: Factorial design and male physicians define scope; exposure to vitamins is not verified selective intracellular lesion removal.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[48] Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Shows: SELECT follow-up found higher prostate-cancer incidence with vitamin E and no preventive selenium benefit.

Does not show: This tests prostate-cancer prevention in men, not a generic antioxidant mechanism across all tissues.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[49] MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Shows: HPS increased circulating vitamin levels substantially without reducing mortality, vascular events or cancer over five years.

Does not show: Blood exposure is established, but selective tissue radical-damage engagement and biological-aging mediation are not.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[50] Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.

Shows: WHS found null primary cardiovascular/cancer outcomes and total mortality despite a secondary cardiovascular-death reduction.

Does not show: The favorable secondary endpoint must be retained but does not establish an overall healthspan or aging-rate benefit.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[51] The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.

Shows: ATBC beta-carotene increased lung cancer and total mortality; vitamin E did not lower total mortality.

Does not show: Male smokers and particular doses define scope; secondary prostate and hemorrhagic-stroke findings are endpoint-specific.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[52] G6PD protects from oxidative damage and improves healthspan in mice.

Shows: G6PD transgenic mice had higher NADPH, lower oxidative damage, better age-related function and longer female median survival.

Does not show: NADPH has multiple biological roles; sex-specific survival does not establish radical-damage primacy across mammals.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[53] Deleterious consequences of antioxidant supplementation on lifespan in a wild-derived mammal.

Shows: Vitamin C/E lowered liver lipid peroxidation but shortened field-vole survival in both temperature settings.

Does not show: DNA damage was unchanged and species-specific toxicity or signalling can differ from mouse and human effects.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[54] Premature ageing in mice expressing defective mitochondrial DNA polymerase.

Shows: Proofreading-deficient PolG mice developed mutations, shortened life and progeroid features.

Does not show: Forced mutation burden is not proof that radical damage normally initiates organismal aging.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[55] Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging.

Shows: A separate PolG model associated progeria with mtDNA mutations and apoptosis without increased oxidative-stress markers.

Does not show: Absence of tested markers is not absence of every transient ROS event; this mainly challenges a mitochondrial vicious cycle.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[56] Mice lacking the mitochondrial exonuclease MGME1 accumulate mtDNA deletions without developing progeria.

Shows: Mgme1 loss generated mitochondrial deletions without progeria.

Does not show: Different mutation spectra and distributions constrain inference; mitochondrial defects cannot be treated as interchangeable aging causes.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[57] Random mtDNA deletions and functional consequence in aged human skeletal muscle.

Shows: Aged human muscle accumulated mtDNA deletions and showed lower respiratory-complex activity.

Does not show: Cross-sectional deletions and function do not establish radical origin or a causal normal-aging rate mechanism.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[58] Liver specific expression of Cu/ZnSOD extends the lifespan of Sod1 null mice.

Shows: Liver SOD1 restoration partly rescued Sod1-null longevity and hepatic pathology without rescuing muscle deficits.

Does not show: Organ-specific rescue in severe deficiency suggests lesion-specific mortality; normal mouse aging remains a distinct question.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[59] High oxidative damage levels in the longest-living rodent, the naked mole-rat.

Shows: Long-lived naked mole-rats had higher measured oxidative damage than comparable mice.

Does not show: Interspecies ecology, repair and tolerance confound causality; high damage contradicts a simple quantitative monotonic model only.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[60] The p66Shc knocked out mice are short lived under natural condition.

Shows: p66Shc deletion was counterselected under outdoor food competition and cold, with energetic and reproductive deficits.

Does not show: Extrinsic hazards differ from protected-laboratory aging; environmental dependence is a boundary, not a direct aging-rate measurement.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[61] The influence of Shc proteins on life span in mice.

Shows: Two institutions found no general p66Shc survival benefit across sexes/backgrounds, apart from a limited calorie-restriction survival percentile.

Does not show: The partial favorable result does not reproduce the original overall longevity claim; protein pleiotropy persists.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[62] Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males.

Shows: Three-site heterogeneous mouse tests found male-specific median-life benefit from NDGA and different effects of metabolic comparators.

Does not show: Drug effects cannot be assigned to antioxidant chemistry without mediation; female and maximum-survival boundaries matter.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[63] Nordihydroguaiaretic Acid Extends the Lifespan of Drosophila and Mice, Increases Mortality-Related Tumors and Hemorrhagic Diathesis, and Alters Energy Homeostasis in Mice.

Shows: NDGA extended fly/mouse survival in selected dosing conditions but increased severe terminal pathology in mice.

Does not show: Survival benefit and health benefit diverge; dose-unit inconsistencies in the abstract require original dosing confirmation before numerical reuse.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[64] Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice.

Shows: ITP NDGA and aspirin increased male median survival across sites without a significant 90th-percentile-survival effect.

Does not show: Shared ITP methods and multifactorial drug actions do not isolate radical-damage mediation or generalize to females.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[65] Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice.

Shows: NAC extended male heterogeneous mouse life, while later-started comparators were null.

Does not show: The authors identify inadvertent dietary restriction as a possible explanation; it is not a clean antioxidant-mechanism test.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[66] Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer.

Shows: ITP replicated male NDGA median-life extension without maximal-life extension and found male benefit with an Nrf2-inducing mixture.

Does not show: Additional cohorts share platform and controls; Nrf2 signalling and botanical mixtures are not selective damage removal.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[67] Antioxidants green tea extract and nordihydroguaiaretic acid confer species and strain-specific lifespan and health effects in Caenorhabditis nematodes.

Shows: Three-site nematode tests found GTE/NDGA benefits and harms varying by species, strain and manual versus automated assay.

Does not show: Original body shows functional and stress-resistance outcomes dissociate from lifespan; scanner light and handling differences remain possible mechanisms.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Materials and methods, 2:Results. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[68] FOXO-regulated OSER1 reduces oxidative stress and extends lifespan in multiple species.

Shows: OSER1 perturbation altered oxidative stress and lifespan in multiple invertebrates; human variants associated with longevity.

Does not show: Protein mitochondrial/reproductive functions and observational human genetics do not isolate damage mediation or human necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• SHA256.txt
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• free-radical-aging.review.md
• free-radical-aging.scorecard.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 68 · load-bearing claims: 72 · verified: 72 · unverified: 0 · contradicted: 0 · schema 5.3